EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...

European Union seeks input from rival pharmaceutical firms on Novo Holding $16.5 billion acquisition of Catalent.

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

By Foo Yun Chee and Maggie Fick BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear ...

周二，合同药品制造商Catalent（纽交所代码：CTLT）公布的第一季度收入未能达到华尔街预期。该公司目前正在被诺和诺德公司旗下的Novo Holdings收购，本季度出现了意外亏损。 Catalent以提供注射器和注射笔的无菌填充和包装服务而闻名，是诺和诺德公司（纽交所代码：NVO）Wegovy减肥药的主要供应商。今年2月，持有诺和诺德公司控股权的Novo Holdings启动了对Catale ...

Nov 5 (Reuters) - Contract drug manufacturer Catalent (CTLT.N), opens new tab, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall ...

根据最近的SEC文件显示，Catalent, Inc. (NYSE:CTLT)的董事Ryan Michelle R近期出售了2,800股公司普通股。每股售价为59.70美元，总交易价值为167,160美元。此次出售后，Ryan Michelle R现持有10,835股，包括限制性股票单位。这些股票的出售是为了支付之前根据Catalent非雇员董事薪酬计划授予的限制性股票单位相关的税款。

BRUSSELS/LONDON (Reuters) - EU antitrust regulators have asked pharma rivals and customers for feedback in four business ...

Following the closing of our transaction, as a private company under Novo Holdings’ ownership, Catalent will continue to operate as a leading global, independent, full-service CDMO. Catalent’s ...

Catalent (CTLT) issued the following open letter to customers: “I want to correct a few key inaccuracies that have been reported in the press regarding Novo Holdings’ pending acquisition of ...

Alessandro Maselli will remain president and CEO of Catalent (NYSE:CTLT) after its acquisition by Novo Holdings, according to an open letter to customers. In the letter addressing customers ...